VANCOUVER, June 17, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) is pleased to announce that the patent for
TFC-1067 entitled "Gem Difluorocompounds as Depigmenting or
Lightening Agents" was granted in the USA, as expected, and will be published in the
official database in the coming month. To date, the TFC-1067 skin
lightening patent has been granted in Germany, France, United
Kingdom and now the US. Further TFC-1067 patent applications
are in the patent pending status in multiple other countries while
they go through the normal approval process.
TFC-1067, Sirona's proprietary skin lightening compound, is
superior to current actives on the market, safe and free of
hydroquinone. The compound has undergone extensive testing, both
preclinical and clinical, including a double blinded study for
dyschromia in the US. Clinical results were received in late
February 2019 and showed the compound
to be superior to hydroquinone in the treatment of dyschromia with
no adverse side effects. Sirona is currently in advanced
negotiations in North America and
Asia in regards to licensing
rights for TFC-1067.
"This patent grant in one of the largest skin care markets is
another important milestone for TFC-1067. The patent application
was without concern to our potential partners as determined by
their IP lawyers however it is an important and exciting milestone
to reach," said Dr. Howard Verrico,
CEO of Sirona Biochem. "This will allow our potential US partners'
absolute IP certainty to move forward with their product marketing
plans."
The global skin lightening market is expected to reach
$23 Billion USD by
20221.
About Sirona Biochem Corp
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
1
https://www.factmr.com/report/309/skin-lightening-products-market
SOURCE Sirona Biochem Corp.